Target ALS is a nonprofit biomedical research organization dedicated to accelerating the development of effective treatments for amyotrophic lateral sclerosis (ALS) by investing in collaborative research, innovative drug discovery platforms, and partnerships between academia and industry.
Biomedical research funding, rare disease research incentives, public-private research partnerships, expanded federal funding for ALS research, and policies that accelerate drug development and regulatory approval for neurodegenerative diseases.
Philanthropic donations from individuals, families, foundations, and corporate partners
Academic research institutions, biotechnology and pharmaceutical companies, ALS research consortia, and patient advocacy organizations
Non-profit organization
